Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.

Notably, COVID severity metrics, including all-cause or hospital mortality, hospital LOS, as well as higher levels of respiratory support via HFNC, NIV, or IMV, all trended in the direction of sotrovimab benefit but were underpowered and did not reach statistical significance.

also in 111,027 other papers